Lexeo Therapeutics, Inc.

LXEO Nasdaq SEC CIK 1907108
Follow Lexeo Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$38.3M −88.8% vs same quarter last year
EPS, diluted −$0.43 −30.3% vs same quarter last year
Operating cash flow −$28.6M +3.3% vs same quarter last year
Operating income −$40.4M −86.6% vs same quarter last year
Net income by quarter
−$25.9M
−$32.7M
−$26.1M
−$20.3M
−$21M
−$20.2M
−$25.9M
−$38.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$100M−$75M−$50M−$25M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$100M
FY24−$98.3M
FY23−$66.4M
FY22−$59.3M
FY21-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$99M
FY24−$81.6M
FY23−$59.6M
FY22−$55.2M
FY21-